ANSAIT
Melanoma, il primo vaccino 'su misura' riduce il rischio di recidiva del 42%
Con tecnologia a mRna, di tipo terapeutico. Personalizzato sul tumore del singolo paziente
🇮🇹 Italia / Italiano
The world, in perspective.
Fresh headlines from around the world. Gaming, politics, technology and everything in between.
Allnira republishes accessible articles under owner-declared permissions, with original authors, publishers and image credits. Automatic cloud imports run hourly; open pages check for updates every 15 seconds. Publication delays depend on each feed.